AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KALA BIO, Inc. Director's Dealing 2021

Jun 29, 2021

35091_dirs_2021-06-29_64ddae50-de4a-4912-8e1c-4d34d6095922.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2021-06-28

Reporting Person: Bazemore Todd (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-28	Common Stock	S	2911	$5.77	Disposed		Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	42	Indirect

Footnotes

F1: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2: Includes 118,000 unvested RSUs.

F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.